Parallel Trade - US Lawmakers allow imported prescriptions drugs

"Parallel Trade acts as an important driving force for market integration where there are important differences in price between member states"

- European Commission Communication on the single market in pharmaceuticals

Parallel trade is on the verge of breaking its confines of the EU and diffusing into other global markets. This global practice is far from simple, and the loopholes that have made it possible refuse to close. Whether you think parallel trade is a benefit or a cost, the reality is that it is affecting the whole pharma industry on a wide scale. It started out a North-South divide but even this is changing. The European Commission and other trade regulation bodies won’t protect the pharma companies pricing structures.

Although consumers may think that imported drugs into the US come from Canada, UK, or other Western European nations, it’s impossible to definitively verify an imported drug’s country of origin.

Do developing countries see parallel trade as a benefit for cheap drugs and if so will it remain a benefit?
This year how much will pharma companies’ profits be threatened by parallel trade?
With individual drugs already being bought in Canada and Mexico will large scale parallel trade become a reality in the US as there are no price controls in place?
The US market is such an attractive market for parallel traders. How will the enlargement of the EU, to 27 affect parallel trade?
Patients, general practitioners, healthcare agencies and national governments are all benefiting from this gray market import. However, there are actual ’real’ winners in this trade, parallel traders themselves. They gain the most benefit from such a trade, which is pure profit. On the other hand, pharma companies are blaming parallel trade, for huge losses in revenue, which in affect lowers innovation. Parallel trade is seen as a gateway for counterfeit drugs entering the supply chain.

"In the European Union, products pass freely from one member nation to another - through a system called ’parallel trade.’ Consequently, drugs sold in England may actually have originated in a country with less rigorous safety standards, such as Cyprus or Latvia". Warwick News

The latest case of counterfeit drugs entering the UK supply chain was that of Eli Lilly’s antipsychotic drug, Zyprexa and Sanofi-Aventis and Bristol Myers Squibb’s Plavix. Three batches were recalled by the MHRA. Isn’t this enough evidence that parallel trade is having a negative affect on the pharma industry? Find out by buying this report.

Does parallel trade diminish the quality and safety of drugs? Isn’t repackaging a great issue when it comes to parallel trade? Isn’t the Internet is a great medium for a form of parallel trade? Many important questions that need answers.

Why You Must Buy This Report:

This 130+ paged report features key figures, including graphs and charts, important tables, news, insights, the latest developments in the parallel trade market with up-to-date analysis.

This report will give you the understanding you require to gain that competitive edge in the parallel trade market. This controversial practice is a hot topic in the pharma industry. Therefore, it is vital that the latest parallel trade report is brought without fail.

With in depth analysis of key markets, and the latest information on parallel trade, this report is vital to grasp an understanding of parallel trade.

Key questions that this report answers:

Why aren’t regulatory bodies protecting pharma companies from parallel trade?
What are the affects of parallel trade on each segment of the market?
Is it possible for pharma companies to protect themselves legally from?
What price link can pharma companies establish that will halt parallel trade without reducing profits further?
What liability do pharma companies face through repackaging when aligned with parallel trade?
How can big pharma use the internet to combat parallel trade?
How does parallel trade (re-importation) affect the US and Canada?
 

Format: Online access to report